iTeos Therapeutics ITOS 深 沪
等待开盘 08-26 09:30:00 美东时间
10.13
-0.060
-0.59%
华盛通- 最 高10.20
- 今 开10.18
- 成交量 102.48万股
- 最 低 10.11
- 昨 收 10.19
- 总市值 3.88亿
- 52周最高 17.63
- 市盈率 静 --
- 换手率 2.68%
- 52周最低 4.80
- 委 比 19.46%
- 总股本 3827.38万
- 历史最高 52.43
- 量 比 1.06
- 振 幅 0.88%
- 历史最低 4.80
- 每 手 1
- 风险率 2.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK and iTeos Advance Immunotherapy Study for Lung Cancer
GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeut...
08-16 00:25
Wells Fargo Maintains Equal-Weight on ITeos Therapeutics, Lowers Price Target to $11
Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:ITOS) with a Equal-Weight and lowers the price target from $12 to $11.
08-07 22:48
ITeos Therapeutics Q2 EPS $(1.81) Misses $(0.95) Estimate
ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(0.95) by 89.73 percent. This is a 905.56 percent decrease over losses of $(0.18) per share
08-06 20:32
Concentra Biosciences To Acquire iTeos For $10.047 In Cash Per Share Plus One Non-Transferable Contingent Value Right
iTeos Therapeutics, Inc. ("iTeos") (NASDAQ:ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire iTeos for $10.047 in cash per share of
07-21 19:30
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
iTeos Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, under which Concentra will acquire iTeos for $10.047 per share of common stock, plus a contingent value right (CVR). The iTeos board unanimously approved the agreement, deeming it in the best interest of all stockholders. The transaction will commence with a tender offer by August 1, 2025, subject to conditions including shareholder majority and $475 mil...
07-21 11:29
Tim Van Hauwermeiren Resigns from iTeos Board
iTeos Therapeutics ( ($ITOS) ) has shared an update. On June 1, 2025, Tim Van H...
06-06 05:51
美股牛股 | 生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功
生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功；Joby Aviation大涨28%，获丰田汽车2.5亿美元战略投资>>
05-29 19:18
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
iTeos Therapeutics Announces Strategic Wind Down Plan
iTeos Therapeutics ( ($ITOS) ) has issued an update. On May 28, 2025, iTeos The...
05-28 20:58
iTeos surges on plans to end operations
iTeos Therapeutics (NASDAQ:ITOS) added ~25% in the premarket on Wednesday after the immuno-oncology drug developer announced plans to wind down operations as an outcome of a strategic review aimed at ...
05-28 20:53
